Trial result ·
First-line hetrombopag combined with immunosuppressive therapy for paediatric severe aplastic anaemia: A prospective randomized controlled trial.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This trial looked at children with severe aplastic anaemia (SAA). All 54 children had just been diagnosed. They were put into groups by chance. One group of 27 got standard drugs that calm the immune system. The other 27 got the same drugs plus hetrombopag. The trial took place at one centre. The main goal was full response after 6 months.
What they found
At 6 months, full response was similar in both groups. Overall response at 6 months was the same in both groups. At 12 months, overall response was still the same. Full response at 12 months did not differ in a clear way. Time to response also showed no clear difference. In children older than 9 years, full response at 3 months was higher with hetrombopag. The hetrombopag group had 8 severe side effects, mostly raised liver enzymes. None of these made anyone stop treatment. Rates of clonal events were similar in both groups.
What it means for patients
Adding hetrombopag to first treatment did not clearly improve response in these children. This held both early on and later. The authors say giving both drugs from the start is not needed for most patients.
Why it is not certain yet
The trial was run at only one centre. It included 54 children. The abstract reports results up to 12 months. It does not say what happened after that. It does not say if the older-child result held at 12 months.
Source
First-line hetrombopag combined with immunosuppressive therapy for paediatric severe aplastic anaemia: A prospective randomized controlled trial.
PubMed · PMID 42661530We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Aplastic anaemia publications